Developing QC Products for CF Testing

An exclusive agreement has been signed by AcroMetrix Corp. (Dallas, TX, USA) with the Children's Hospital Medical Center of Akron (CHMCA, OH, USA) to develop and commercialize quality control (QC) products for cystic fibrosis (CF) testing using CHMCA's new proprietary technology.

New recommendations and guidelines have been recommended by the American College of Medical Genetics and the American College of Obstetricians and Gynecologists for CF carrier testing in a population-based screening program. This screening for high-prevalence mutations using molecular diagnostic test methods identifies carrier couples with a one-in-four risk for affected offspring with each pregnancy, and offers them genetic counseling and various reproductive options. Because of the technical complexity of these tests, it is also recommended that laboratories conducting CF carrier screening comply with stringent quality assurance guidelines.

"This agreement with CHMCA will result in innovative quality control products designed to increase the accuracy and reliability of cystic fibrosis testing,” said Michael J. Eck, CEO of AcroMetrix. The company, which also has a facility in Alkmaar, The Netherlands, provides a line of molecular diagnostic quality control products that assist laboratories in meeting current government regulations and recommendations regarding quality assurance.





Related Links:
AcroMetrix